Status:
UNKNOWN
Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Opioid-use Disorder
Pain, Acute
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The aim of this study is to determine the effect of continuation of buprenorphine/naloxone in patients with history of Opioid Use Disorder (OUD) scheduled for surgery compared to reduced dose buprenor...
Detailed Description
Opioid use disorder (OUD) is characterized by non-remitting cycles of remission and opioid abuse relapse. It is associated with a high rate of psychiatric and physical co-morbidity when left untreated...
Eligibility Criteria
Inclusion
- currently taking buprenorphine or buprenorphine/naloxone daily for treatment of opioid use disorder by DSM-V criteria
- on buprenorphine or buprenorphine/naloxone dose of greater than 8mg for at least 30 days
- ASA health class I-III
Exclusion
- Unable to consent to the study
- Significant pulmonary or cardiac disease
- Renal insufficiency with a glomerular filtration rate less than 30ml/min
- Liver cirrhosis with a Model for End-Stage Liver Disease (MELD) score of greater than 25
Key Trial Info
Start Date :
October 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 26 2022
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03266445
Start Date
October 5 2018
End Date
February 26 2022
Last Update
October 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.